David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.
David Swoboda, MD
Advertisement
David Swoboda, MD, is the clinical director of leukemia at Tampa General Hospital Cancer Institute and an assistant professor at the University of South Florida Morsani College of Medicine in Tampa.
Articles by David Swoboda, MD
Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.
Advertisement
Latest Updated Articles
Dr Swoboda on the Role of TKIs in Chronic Myeloid LeukemiaPublished: May 30th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5